Hoth Therapeutics’ GDNF shows efficacy in obesity prevention and reversal

Hoth Therapeutics (HOTH) announced preclinical findings that highlight the potential of Glial Cell Line-Derived Neurotrophic Factor, or GDNF, as a revolutionary treatment for obesity. The study, conducted in GDNF-transgenic models, demonstrated that GDNF significantly reduces fat accumulation, enhances metabolism, and improves insulin sensitivity, even under high-fat diet conditions. Key findings from the study include: protection against high-fat diet-induced obesity – GDNF-tg mice exhibited significantly lower body weight and reduced fat deposition despite consuming a high-fat diet. Enhanced fat burning and energy expenditure – GDNF increased basal metabolic rate, oxygen consumption, and carbon dioxide production, leading to higher energy expenditure without changes in food intake. Inhibition of fat cell formation – GDNF suppressed key genes involved in fat storage, including PPAR-gamma, FASN, and SREBF1, while promoting fat oxidation pathways. Improved insulin sensitivity and glucose regulation – GDNF-tg mice showed enhanced glucose tolerance and lower serum leptin levels, markers of improved metabolic health. Reduced fatty liver disease – GDNF prevented hepatic steatosis, or fat accumulation in the liver, a common obesity-related complication. The company plans to initiate further preclinical and clinical development efforts to bring this potential therapy closer to patients in need.